Zoetis Inc
NYSE:ZTS

Watchlist Manager
Zoetis Inc Logo
Zoetis Inc
NYSE:ZTS
Watchlist
Price: 176.96 USD 0.14% Market Closed
Market Cap: 79.8B USD
Have any thoughts about
Zoetis Inc?
Write Note

Zoetis Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Zoetis Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Zoetis Inc
NYSE:ZTS
Income from Continuing Operations
$2.4B
CAGR 3-Years
7%
CAGR 5-Years
11%
CAGR 10-Years
16%
Johnson & Johnson
NYSE:JNJ
Income from Continuing Operations
$14.8B
CAGR 3-Years
-6%
CAGR 5-Years
1%
CAGR 10-Years
-2%
Bristol-Myers Squibb Co
NYSE:BMY
Income from Continuing Operations
-$7.2B
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Income from Continuing Operations
$4.3B
CAGR 3-Years
-40%
CAGR 5-Years
4%
CAGR 10-Years
-9%
Merck & Co Inc
NYSE:MRK
Income from Continuing Operations
$12.2B
CAGR 3-Years
27%
CAGR 5-Years
5%
CAGR 10-Years
8%
Eli Lilly and Co
NYSE:LLY
Income from Continuing Operations
$8.4B
CAGR 3-Years
12%
CAGR 5-Years
14%
CAGR 10-Years
12%
No Stocks Found

Zoetis Inc
Glance View

Market Cap
79.9B USD
Industry
Pharmaceuticals

Zoetis Inc. is a leading global animal health company dedicated to advancing animal care through innovative solutions that enhance the well-being and productivity of livestock and companion animals. Established in 1952 as a former division of the pharmaceutical giant Pfizer, Zoetis transitioned into its standalone identity in 2013 and has since carved out a significant niche in the growing market for animal health products. With a diverse portfolio that includes vaccines, parasiticides, and diagnostic tools, the company serves farmers, veterinarians, and pet owners, contributing to the health of food-producing animals and pets alike. The robust demand for high-quality animal health products—driven by increasing global food consumption and a growing pet population—positions Zoetis for sustainable growth and offers investors a compelling opportunity. Financially, Zoetis has demonstrated consistent revenue growth, leveraging its strong market presence and commitment to research and development. The company's strategic investments in new technologies and targeted acquisitions have strengthened its position in key market segments. With a focus on driving innovation and addressing changing consumer needs, Zoetis is poised to benefit from emerging trends such as increased attention to food safety and animal welfare. For investors, this translates to a resilient business model with solid long-term prospects, backed by a proven leadership team and a commitment to maintaining a competitive edge through continuous advancement in animal health solutions.

ZTS Intrinsic Value
119.41 USD
Overvaluation 33%
Intrinsic Value
Price

See Also

What is Zoetis Inc's Income from Continuing Operations?
Income from Continuing Operations
2.4B USD

Based on the financial report for Sep 30, 2024, Zoetis Inc's Income from Continuing Operations amounts to 2.4B USD.

What is Zoetis Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
16%

Over the last year, the Income from Continuing Operations growth was 7%. The average annual Income from Continuing Operations growth rates for Zoetis Inc have been 7% over the past three years , 11% over the past five years , and 16% over the past ten years .

Back to Top